Morgan Stanley lowered the firm’s price target on Alnylam (ALNY) to $268 from $284 and keeps an Equal Weight rating on the shares. The firm is ...

As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, ...

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc.

President Trump’s newly announced tariff policy has done more than just push the stock markets deeper into correction territory — the sudden ...

Research analysts at Leerink Partnrs dropped their FY2026 earnings per share estimates for Alnylam Pharmaceuticals in a ...

Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Alnylam ...

Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Alnylam has got the go-ahead for a second – Amvuttra – which has a simpler ...

NICE' has said that Wainzua can be used as an alternative to Alnylam's Amvuttra (vutrisiran), which was recommended for NHS use last year. Amvuttra is dosed every three months via a pre-filled ...

It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia.